147 related articles for article (PubMed ID: 26481897)
1. Mechanical insights of oxythiamine compound as potent inhibitor for human transketolase-like protein 1 (TKTL1 protein).
Mariadasse R; Biswal J; Jayaprakash P; Rao GR; Choubey SK; Rajendran S; Jeyakanthan J
J Recept Signal Transduct Res; 2016; 36(3):233-42. PubMed ID: 26481897
[TBL] [Abstract][Full Text] [Related]
2. The human transketolase-like proteins TKTL1 and TKTL2 are bona fide transketolases.
Deshpande GP; Patterton HG; Faadiel Essop M
BMC Struct Biol; 2019 Jan; 19(1):2. PubMed ID: 30646877
[TBL] [Abstract][Full Text] [Related]
3. A δ38 deletion variant of human transketolase as a model of transketolase-like protein 1 exhibits no enzymatic activity.
Schneider S; Lüdtke S; Schröder-Tittmann K; Wechsler C; Meyer D; Tittmann K
PLoS One; 2012; 7(10):e48321. PubMed ID: 23118983
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of plasmodial transketolases and identification of potential inhibitors: an in silico study.
Boateng RA; Tastan Bishop Ö; Musyoka TM
Malar J; 2020 Nov; 19(1):442. PubMed ID: 33256744
[TBL] [Abstract][Full Text] [Related]
5. Transketolase-like protein 1 confers resistance to serum withdrawal in vitro.
Hartmannsberger D; Mack B; Eggert C; Denzel S; Stepp H; Betz CS; Gires O
Cancer Lett; 2011 Jan; 300(1):20-9. PubMed ID: 20884117
[TBL] [Abstract][Full Text] [Related]
6. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells.
Xu X; Zur Hausen A; Coy JF; Löchelt M
Int J Cancer; 2009 Mar; 124(6):1330-7. PubMed ID: 19065656
[TBL] [Abstract][Full Text] [Related]
7. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer.
Földi M; Stickeler E; Bau L; Kretz O; Watermann D; Gitsch G; Kayser G; Zur Hausen A; Coy JF
Oncol Rep; 2007 Apr; 17(4):841-5. PubMed ID: 17342325
[TBL] [Abstract][Full Text] [Related]
8. [Specific and metabolic effect of oxythiamine].
Gorbach ZV; Maglysh SS; Zabrodskaia SV
Ukr Biokhim Zh (1978); 1981; 53(6):69-73. PubMed ID: 6275590
[TBL] [Abstract][Full Text] [Related]
9. Is transketolase-like protein, TKTL1, transketolase?
Meshalkina LE; Drutsa VL; Koroleva ON; Solovjeva ON; Kochetov GA
Biochim Biophys Acta; 2013 Mar; 1832(3):387-90. PubMed ID: 23261987
[TBL] [Abstract][Full Text] [Related]
10. Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo.
Yuan W; Wu S; Guo J; Chen Z; Ge J; Yang P; Hu B; Chen Z
Cancer Biol Ther; 2010 May; 9(9):710-6. PubMed ID: 20200485
[TBL] [Abstract][Full Text] [Related]
11. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.
Jayachandran A; Lo PH; Chueh AC; Prithviraj P; Molania R; Davalos-Salas M; Anaka M; Walkiewicz M; Cebon J; Behren A
BMC Cancer; 2016 Feb; 16():134. PubMed ID: 26907172
[TBL] [Abstract][Full Text] [Related]
12. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted.
Langbein S; Zerilli M; Zur Hausen A; Staiger W; Rensch-Boschert K; Lukan N; Popa J; Ternullo MP; Steidler A; Weiss C; Grobholz R; Willeke F; Alken P; Stassi G; Schubert P; Coy JF
Br J Cancer; 2006 Feb; 94(4):578-85. PubMed ID: 16465194
[TBL] [Abstract][Full Text] [Related]
13. EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer.
Coy JF
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28425973
[TBL] [Abstract][Full Text] [Related]
14. Evidence for transketolase-like TKTL1 flux in CHO cells based on parallel labeling experiments and (13)C-metabolic flux analysis.
Ahn WS; Crown SB; Antoniewicz MR
Metab Eng; 2016 Sep; 37():72-78. PubMed ID: 27174718
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational Acylations of the Rat Brain Transketolase Discriminate the Enzyme Responses to Inhibitors of ThDP-Dependent Enzymes or Thiamine Transport.
Aleshin VA; Kaehne T; Maslova MV; Graf AV; Bunik VI
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255994
[TBL] [Abstract][Full Text] [Related]
16. Homology modeling of human transketolase: description of critical sites useful for drug design and study of the cofactor binding mode.
Obiol-Pardo C; Rubio-Martinez J
J Mol Graph Model; 2009 Feb; 27(6):723-34. PubMed ID: 19111488
[TBL] [Abstract][Full Text] [Related]
17. The crystal structure of human transketolase and new insights into its mode of action.
Mitschke L; Parthier C; Schröder-Tittmann K; Coy J; Lüdtke S; Tittmann K
J Biol Chem; 2010 Oct; 285(41):31559-70. PubMed ID: 20667822
[TBL] [Abstract][Full Text] [Related]
18. Dual effects for lovastatin in anaplastic thyroid cancer: the pivotal effect of transketolase (TKT) on lovastatin and tumor proliferation.
Wang CY; Shui HA; Chang TC
J Investig Med; 2018 Jun; 66(5):1-9. PubMed ID: 29502067
[TBL] [Abstract][Full Text] [Related]
19. A key role for transketolase-like 1 in tumor metabolic reprogramming.
Diaz-Moralli S; Aguilar E; Marin S; Coy JF; Dewerchin M; Antoniewicz MR; Meca-Cortés O; Notebaert L; Ghesquière B; Eelen G; Thomson TM; Carmeliet P; Cascante M
Oncotarget; 2016 Aug; 7(32):51875-51897. PubMed ID: 27391434
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma.
Zhang S; Yue JX; Yang JH; Cai PC; Kong WJ
Cancer Biol Ther; 2008 Apr; 7(4):517-22. PubMed ID: 18296915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
